Document is current
Any future updates will be listed below
-
Authors
Yang, Xing
Huang, Ryan
Fang, Meng https://orcid.org/0009-0000-0122-416X
He, Yubo
Xie, Jingjing
Liu, Xiaoye
Zhang, Chengcheng
Lou, Qi
Deng, Mi
Xiong, Wei
Lewis, Cheryl
Sadek, Zade
Gupta, Ankit https://orcid.org/0000-0001-5295-180X
Chen, Lianqi https://orcid.org/0000-0002-0392-0633
Zhang, Xuewu https://orcid.org/0000-0002-3634-6711
Guo, Lei
Xu, Lin https://orcid.org/0000-0001-5815-4457
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
Zhang, Cheng Cheng https://orcid.org/0000-0003-4763-3887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA248736, R01CA263079)
Cancer Prevention and Research Institute of Texas (RP220032, RP15150551, RP190561)
Lung Cancer SPORE Development Research Program Immune-Onc Therapeutics, Inc
the CPRIT training grant
U.S. Department of Health & Human Services | National Institutes of Health (P30CA142543, R35GM130289)
Welch Foundation (I-1702, AU-0042-20030616)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 18 June 2025
First Online: 24 July 2025
Competing interests
: Authors R.H., Y.H., M.D., W.X., N.Z., Z.A. and C.C.Z. are listed as inventors on relevant patent applications that were exclusively licensed to Immune-Onc Therapeutics by the Board of Regents of the University of Texas System. Authors M.D., Z.A., N.Z. and C.C.Z. hold equity in and had Sponsored Research Agreements with Immune-Onc Therapeutics. The University of Texas has a financial interest in Immune-Onc in the form of equity and licensing. The other authors declare no competing interests.
